Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 2977-2985

  Gilewski, Teresa A ^a   Ragupathi, Govind ^a   Dickler, Maura ^a   Powell, Shemeeakah ^a   Bhuta, Sonal ^a   Panageas, Kathy ^a   Koganty, R Rao ^b   Chin Eng, Jeannette ^a   Hudis, Clifford ^a   Norton, Larry ^a   Houghton, Alan N ^a   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; GOSERELIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGIC AGENT; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE LIMPET HEMOCYANIN PLUS SIALYL TN; MEGESTROL ACETATE; MUCIN; QS 21; SIALYS TN; TAMOXIFEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BLISTER; BREAST CANCER; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN CELL; IMMUNIZATION; INJECTION SITE REACTION; LEUKOPENIA; LOCAL SKIN REACTION; MUSCLE RIGIDITY; MYALGIA; NAUSEA; NEUTROPENIA; OCCULT BLOOD; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SIDE EFFECT; THROMBOCYTOPENIA; URTICARIA; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RISK; SAPONINS;

EID: 34249814310     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2189     Document Type: Article

References (50)

1. Springer GF. T and Tn, General carcinoma autoantigens. Science 1984;224:1198-206.
2. Livingston PO, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. Previous experience and future plans. Cancer Immunol Immunother 1997;45:10-9.
3. Gold DV, Mattes MJ. Monoclonal antibody B72.3 reacts with a core region structure of O-linked carbohydrates. Tumour Biol 1988;9:137-44.
4. Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982;29:539-45.
5. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2->6α-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:2214-20.
6. Kurosaka A, Kitagawa H, Fukui S, et al. A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAcα 2-> 6 galNAc, in mucin-type glycoproteins. J Biol Chem 1988;263:8724-6.
7. Siddiki B, Ho JJ, Huang J, et al. Monoclonal antibody directed against colon cancer mucin has high specificity for malignancy. Int J Cancer 1993;54:467-74.
8. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118-24.
9. Schuessler MH, Pintado S, Welt S, et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer 1991;47:180-7.
10. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-TN, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
11. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 1997;73:50-6.
12. Yonezawa S, Tachikawa T, Shin S, Sato E. Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas. Am J Clin Pathol 1992;98:167-74.
13. Hill HD, Reynolds JA, Hill RL. Purification, composition, molecular weight, and subunit structure of ovine submaxillary mucin. J Biol Chem 1977;252:3791-8.
14. O'Boyle KP, Markowitz AL, Khorshidi M, et al. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-> 6) T antigens. Hybridoma 1996;15:401-8.
15. Kinney AY, Sahin A, Vernon SW, et al. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997;80:2240-9.
16. Longenecker BM, Reddish M, Miles D, MacLean GD. Synthetic tumor associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Research 1993;2:151-62.
17. Miles DW, Happerfield LC, Smith P, et al. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994; 70:1272-5.
18. Stein R, Goldenberg DM, Mattes MJ. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int J Cancer 1991;47:163-9.
19. Ogata S, Chen A, Itzkowitz SH. Use of model cell lines to study the biosynthesis and biological role of cancer-associated sialosyl-Tn antigen. Cancer Res 1994;54:4036-44.
20. MacLean GD, Reddish M, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993;36:215-22.
21. Hanisch FG, Uhlenbruck G, Egge H, Peter-Katalinic J. A B72.3 second-generation-monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Galβ[NeuAcα(2-6)]GalNAc. Biol Chem Hoppe Seyler 1989;370:21-6.
22. Lloyd KO, Burchell J, Kudryashov V, Yin BW, Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J Biol Chem 1996;271:33325-34.
23. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992;52:4741-6.
24. Van Rinsum J, Smets LA, Van Rooy H, Van den Eijnden DH. Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialo-oligosaccharides. Int J Cancer 1986;38:915-22.
25. Fung PY, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 1991;51:1170-6.
26. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4:43-9.
27. Yamashita Y, Chung YS, Horie R, Kannagi R, Sowa M. Alterations in gastric mucin with malignant transformation: novel pathway for mucin synthesis. J Natl Cancer Inst 1995;87:441-6.
28. Zhang S, Graeber LA, Helling F, et al. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 1996;56:3315-9.
29. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J Immunol 1991;146:431-7.
30. Zhang S, Walberg LA, Ogata S, et al. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 1995;55: 3364-8.
31. Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J 1997;14:549-60.
32. Nakada H, Inoue M, Numata Y, et al. Epitopic structure of Tn glycophorin A for an anti-tn antibody (MLS 128). Proc Natl Acad Sci U S A 1993;90:2495-9.
33. Ragupathi G, Howard L, Cappello S, et al. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1- carboxylhydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol Immunother 1999;48:1-8.
34. Singhal A, Fohn M, Hakomori S. Induction of -N-acetylgalactosamine-O- serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 1991;51:1406-11.
35. Fung PY, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990;50:4308-14.
36. O'Boyle KP, Zamore R, Adluri S, et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res 1992;52: 5663-7.
37. Adluri S, Helling F, Ogata S, et al. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 1995;41: 185-92.
38. Miles DW, Towlson KE, Graham R, et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74:1292-6.
39. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope sTn-KLH cancer vaccine. J Immunother 1999; 22:54-66.
40. Dickler M, Gilewski T Ragupathi G, et al. Vaccination of breast cancer patients (pts) with no evidence of disease (NED) with sialyl Tn cluster (sTn(c))-keyhole limpet hemocyanin (KLH) conjugate plus adjuvant QS-21: preliminary results. Proc Am Soc Clin Oncol 1997;16:439a.
41. Ragupathi G, Koganty RR, Qiu DX, Lloyd KO, Livingston PO. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn KLH conjugate using a 4- (4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj J 1998;15:217-21.
42. Yao TJ, Begg CB, Livingston PO. Optimal sample size for a series of pilot trials of new agents. Biometrics 1996;52:992-1001.
43. Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-701.
44. Gilewski T, Ragupathi G, Bhuta S, et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A 2001;98:3270-5.
45. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55:2783-8.
46. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-20.
47. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005;174: 5706-12.
48. + lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996;42:303-9.
49. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19:59-68.
50. Miles D, Ibrahim N, Roche H, et al. An international, randomized phase III clinical trial of STn-KLH (Theratope) therapeutic cancer vaccine in metastatic breast cancer patients. Breast Cancer Res Treat 2003;82: S17-8.